A new study from Lund University in Sweden shows that women with low
levels of an anti-stress hormone have an increased risk of getting
breast cancer. The study is the first of its kind on humans and confirms
previous similar observations from animal experiments.The recent findings on a potential new marker for the risk of developing breast cancer are presented in the renowned Journal of Clinical Oncology.
The study focused on a hormone which circulates freely in the blood,
enkephalin, with pain- and anxiety-reducing properties. Enkephalin also
reinforces the immune system by directly affecting immune cells.
"This is the first time the role of enkephalin in breast cancer has
been studied in humans, and the results were surprisingly clear. Among
women with the lowest levels of the hormone, the risk of breast cancer
was more than three times that of the women with the highest levels of
the hormone. This is one of the strongest correlations between cancer
risk and a freely circulating biomarker ever described", said Olle
Melander and Mattias Belting, both professors at Lund University and
consultant physicians at Skåne University Hospital.
The findings were possible thanks to a broad approach combining the
latest knowledge within cancer and cardiovascular research at Lund
University; the study was based on blood samples taken from just over 1
900 women in Malmö. The women were followed up with regard to breast
cancer for an average period of 15 years.The results were adjusted for age, menopause, hormonal treatment,
smoking and other factors which can affect the risk of getting breast
cancer.
The current study confirms a statistical correlation between low
enkephalin concentrations in the blood and increased risk of breast
cancer, and it remains to be seen whether there is a causal relation
showing that a low level of the hormone directly affects tumour
development. The researchers also point out that geographical location
and age, in spite of the adjustments in the study, may be significant.
The average age of the women studied was 57.
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment